Project Grant R01AI187168
Award Date
11/18/24
Completion Date
10/31/29
Dollars Obligated
$405K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14621, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $340,712 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Rochester. The grant, titled "Evaluating the Role of Monocytes in the Development of an Effective HIV Vaccine Response", aims to investigate the role of monocyte subpopulations in regulating the antibody response to HIV vaccines. The research project, scheduled for completion by June 30, 2027,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital to develop targeted vaccine candidates against nontuberculous mycobacterial (NTM) infections. The project aims to evaluate the efficacy of two NTM vaccine candidates - an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine - in mouse models. Key research activities include screening...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $422,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Florida. The grant will fund research to develop a Salmonella-based vaccine that can deliver Francisella type VI secretion system proteins as antigens to induce protective immunity against tularemia, a potentially deadly infectious disease. The research aims to leverage an established Salmonella antigen...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The purpose of this 2-year grant, with a start date of January 23, 2025, is to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BnAbs) for their potential use in a universal influenza vaccine. The research will assess factors such as precursor frequency,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $722,958 to the University of Rochester to investigate the role of monocyte-derived galectin-1 in promoting tissue-resident memory T cell responses against influenza virus. The research aims to (1) study monocyte differentiation during immune memory formation after influenza infection, (2) determine how galectin-1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 2-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) worth $162,000 to The Johns Hopkins University to study how atypical B cells can be used to enhance vaccine responses in immunosuppressed individuals. The research project aims to define populations of immunosuppressed individuals who utilize these atypical CD11c+ B cells, assess their interaction with T cells, and target fatty acid oxidation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,942 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Tech Research Corp to develop self-assembled peptide nanoparticles as a universal influenza vaccine platform. The goal is to use these nanoparticles to present conserved viral antigens, including hemagglutinin stalk, matrix protein 2 ectodomain, and nucleoprotein, in order to elicit broad, protective immune...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $261,846 to New York Medical College to develop an intranasal vaccine against Pseudomonas aeruginosa (PA), a common cause of healthcare-associated infections. The research aims to create a multi-valent vaccine using tobacco mosaic virus as a delivery platform, with the goal of providing broad protection against different...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...